137 related articles for article (PubMed ID: 22432770)
1. Case report of perforation of an ileal neobladder after treatment of rectal cancer with bevacizumab and comment on mechanisms of intestinal perforation associated with bevacizumab.
Liu SV; Gollard R; Iqbal S
J Clin Pharm Ther; 2012 Oct; 37(5):607-9. PubMed ID: 22432770
[TBL] [Abstract][Full Text] [Related]
2. [A case of metachronous gastrointestinal perforation of a patient with metastatic rectal cancer during treatment with bevacizumab-based chemotherapy].
Sadatomo A; Koinuma K; Miki A; Horie H; Yasuda Y
Gan To Kagaku Ryoho; 2013 Jul; 40(7):943-5. PubMed ID: 23863742
[TBL] [Abstract][Full Text] [Related]
3. Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.
Heinzerling JH; Huerta S
Curr Surg; 2006; 63(5):334-7. PubMed ID: 16971205
[TBL] [Abstract][Full Text] [Related]
4. [Two Cases of Bowel Perforation during Chemotherapy with Bevacizumab to Metastatic Rectal Cancer].
Miyake Y; Ikeda K; Murakami M; Oka Y; Nezu R; Kurokawa E; Kikkawa N
Gan To Kagaku Ryoho; 2015 Dec; 42 Suppl 1():75-8. PubMed ID: 26809419
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: report of three cases.
Lordick F; Geinitz H; Theisen J; Sendler A; Sarbia M
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1295-8. PubMed ID: 16503384
[TBL] [Abstract][Full Text] [Related]
6. Gastrointestinal perforation due to bevacizumab in colorectal cancer.
Saif MW; Elfiky A; Salem RR
Ann Surg Oncol; 2007 Jun; 14(6):1860-9. PubMed ID: 17356952
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab-induced bowel perforation.
Sliesoraitis S; Tawfik B
J Am Osteopath Assoc; 2011 Jul; 111(7):437-41. PubMed ID: 21803880
[TBL] [Abstract][Full Text] [Related]
8. [A case of delayed colonic perforation after metallic stent placement for advanced descending colon cancer during bevacizumab-based chemotherapy].
Tanaka I; Hisai H; Miyazaki E; Ono M; Maeda Y; Sato M; Kawasaki R; Gyobu H; Nakajima S; Yamada S; Muramatsu H
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2319-21. PubMed ID: 22202368
[TBL] [Abstract][Full Text] [Related]
9. [Surgical management of bevacizumab-associated peritonitis due to perforation].
Kube R; Meyer F; Bien N; Schmidt C; Mroczkowski P; Dalicho S; Lippert H
Zentralbl Chir; 2009 Sep; 134(5):462-7. PubMed ID: 19757347
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic management of colonic perforation owing to angiogenesis inhibitors.
Ezzedine S; Bege T; Berdah S; Vitton V; Grimaud JC; Barthet M
Surg Laparosc Endosc Percutan Tech; 2010 Dec; 20(6):e230-2. PubMed ID: 21150409
[TBL] [Abstract][Full Text] [Related]
11. "Spontaneous," delayed colon and rectal anastomotic complications associated with bevacizumab therapy.
August DA; Serrano D; Poplin E
J Surg Oncol; 2008 Feb; 97(2):180-5. PubMed ID: 18095268
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-associated fistula formation in postoperative colorectal cancer patients.
Ganapathi AM; Westmoreland T; Tyler D; Mantyh CR
J Am Coll Surg; 2012 Apr; 214(4):582-8; discussion 588-90. PubMed ID: 22321523
[TBL] [Abstract][Full Text] [Related]
13. [Four cases of bevacizumab-related gastrointestinal perforation].
Uchino T; Mishima H; Kimura K; Mori D; Ando K; Nagata H; Kondo R; Kosaka K; Ohashi N; Ito N; Arikawa T; Miyachi M; Suzumura K; Sano T; Nonami T
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2506-8. PubMed ID: 25731572
[TBL] [Abstract][Full Text] [Related]
14. Diaphragmatic rupture, a new complication of Bevacizumab.
Lacaze L; Scotté M
Eur J Surg Oncol; 2012 Nov; 38(11):1079-81. PubMed ID: 22818843
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
[TBL] [Abstract][Full Text] [Related]
16. Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
Richardson DL; Backes FJ; Hurt JD; Seamon LG; Copeland LJ; Fowler JM; Cohn DE; O'Malley DM
Gynecol Oncol; 2010 Jul; 118(1):47-51. PubMed ID: 20382413
[TBL] [Abstract][Full Text] [Related]
17. Interstitial nephritis secondary to bevacizumab treatment in metastatic leiomyosarcoma.
Barakat RK; Singh N; Lal R; Verani RR; Finkel KW; Foringer JR
Ann Pharmacother; 2007 Apr; 41(4):707-10. PubMed ID: 17374619
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.
Akun E; Okutur K; Seber S; Korkmaz T; Aydin K; Bozkurt M; Namal E; Hasbal B; Tecimer C; Demir G
J BUON; 2012; 17(4):669-76. PubMed ID: 23335523
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab and ovarian cancer.
Sato S; Itamochi H
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients.
Borofsky SE; Levine MS; Rubesin SE; Tanyi JL; Chu CS; Lev-Toaff AS
Abdom Imaging; 2013 Apr; 38(2):265-72. PubMed ID: 22627832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]